
|Videos|September 8, 2022
What’s next for Black-tailored prostate cancer risk calculator?
Author(s)Urology Times staff
“[With] some folks, if you don't accurately risk stratify them, you miss your chance to really build that trust as a provider,” says Neil Mistry, MD, MPH.
Advertisement
In this video, Neil Mistry, MD, MPH, and Adam B. Murphy, MD, MBA, MSCI, discuss future research and the take-home message from the abstract, “West-African ancestry can aid prediction of high-grade prostate cancer in Black-tailored risk calculator,” which was presented at the North Central Section of the AUA Annual Meeting in Chicago, Illinois. Mistry is a urology resident and Murphy is an assistant professor of urology and preventive medicine (cancer epidemiology and prevention) at Northwestern University Feinberg School of Medicine in Chicago.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












